Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)

Advances in Therapy

Volumn 32, Issue 11, 2015, Pages 1117-1127

  Walker, David R ^a   Pedrosa, Marcos C ^a   Manthena, Shivaji R ^a   Patel, Nikil ^a   Marx, Steven E ^a  

^a ABBVIE INC   (United States)

Author keywords

Direct acting antivirals; Hepatitis C; Infectious diseases; Real world evidence; Sustained virologic response

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR; DIRECT ACTING ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FISHER EXACT TEST; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT; ADOLESCENT; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84948577572     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0258-5     Document Type: Article

References (21)

1. World Health Association 2015. Hepatitis C fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 4 Sep 2015.
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
3. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;7(348):g3308.
4. Bichoupan K, Martel-Laferriere V, Sachs D, et al. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014;60:1187–95.
5. Bichoupan K, Schwartz JM, Martel-Laferriere V, et al. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther. 2014;39(2):209–16.
6. Backus LI, Belperio PS, Shahoumian TA, et al. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015;42:559–73.
7. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies and challenges. Gastroenterology. 2014;146:1176–92.
8. Johnson SJ, Juday TR, Samp JC, et al. Cost-effectiveness of treating different stages of genotype 1 hepatitis C virus (GT1-HCV) with viekira pak (paritaprevir/ritonavir/ombitasvir and dasabuvir) ± ribavirin compared to no treatment in the United States. Poster presentation at the 50th International Liver Congress, April 22–26 2015, Vienna, Austria.
9. Leidner AJ, Chesson HW, Xu F, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860–9.
10. Flisiak, R. et al, Efficacy and safety of Paritaprevir/r/Ombitasvir/Dasabuvir ± Ribavirin in GT1 HCV infected patients treated in real life settings, presented Viral Hepatitis Congress, Frankfurt, September, 10–12 2015.
11. American Association for the Study of Liver Diseases/Infectious. Diseases Society of America (AASLD/IDSA) HCV guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.
12. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.
13. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.
14. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.
15. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–13.
16. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.
17. Zeuzem S, Jacobson IM, Baykai T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.
18. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–31.
19. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.
20. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450–5.
21. Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of ombitasvir—450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc. 2014;17(4 Suppl 3):19500.